International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases

Key facts

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Principal Investigator

Kenichi Hirano, MD, Ph.D

Department of Cardiovascular Medicine, Faculty of Internal Medicine, Graduate School of Osaka University

Enrollment

120 enrolled

Eligibility

All sexes

Timeline

2014 – 2028

Study locations (15)

• Stanford University, Stanford, California, United States
• Columbia University, New York, New York, United States
• University of Graz, Graz, Styria, Austria
• Peking University First Hospital, Beijing, Beijing Municipality, China
• Pitié-Salpêtrière Hospital, Paris, Paris, France
• Ludwig-Maximilians University, Munich, Bavaria, Germany
• Sapienza University of Rome, Rome, Lazio, Italy
• A.C.O. San Filippo Neri Hospital, Rome, Lazio, Italy
• Catholic University, Milan, Lombardy, Italy
• University of Padova, Padua, Veneto, Italy
• Graduate School of Osaka University, Suita, Osaka, Japan
• National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
• Maastricht University, Maastricht, Limburg, Netherlands
• Harefield Hospital, Harefield, London, United Kingdom
• New Castle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.